These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32325538)

  • 1. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
    Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
    Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
    Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
    Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
    Berntorp E
    Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
    Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
    Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
    Mikovic D; Woodhams BJ; Holmström M; Elezovic I; Antovic A; Mobarrez F; Elfvinge P; Antovic JP
    Int J Lab Hematol; 2012 Feb; 34(1):35-40. PubMed ID: 21707936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.
    Foley JH; Nesheim ME
    J Thromb Haemost; 2009 Mar; 7(3):453-9. PubMed ID: 19087221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.
    Wu C; Kim PY; Swystun LL; Liaw PC; Weitz JI
    J Thromb Haemost; 2016 Feb; 14(2):366-74. PubMed ID: 26663133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma factor VIII enhances venous thrombus formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor.
    Sugita C; Yamashita A; Matsuura Y; Iwakiri T; Okuyama N; Matsuda S; Matsumoto T; Inoue O; Harada A; Kitazawa T; Hattori K; Shima M; Asada Y
    Thromb Haemost; 2013 Jul; 110(1):62-75. PubMed ID: 23636277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation, activity and inactivation of factor VIII in factor VIII products.
    Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
    Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
    Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
    Jiménez-Yuste V; Oldenburg J; Rangarajan S; Kurth MH; Bozzo J; Santagostino E
    Haemophilia; 2016 Jan; 22(1):e71-4. PubMed ID: 26612826
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
    Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.
    Brophy DF; Martin EJ; Mohammed BM; Barrett JC; Kuhn JG; Nolte ME; Wiinberg B; Holmberg HL; Lund J; Salbo R; Waters EK
    Haemophilia; 2017 Nov; 23(6):941-947. PubMed ID: 28750471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
    Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
    Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
    J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.